OLR1 and Peri-Implantitis: Additionally, the downregulation of MMP9 and LOX-1 expression by metalloproteinase inhibitors indicates that Erk1/2, LOX-1, and MMP9 could serve as potential therapeutic targets for treating peri-implantitis (Figure 5).